Skip to content
Fibrosis Icon

Respiratory, Cardiometabolic, & Renal

Fibroproliferative disorders are estimated to contribute to 45% of deaths*. The magnitude of this unmet clinical need is resulting in intense efforts to develop novel therapeutics. The Fibrosis Event Series mission is to enable drug developers to eradicate fibrotic disease.

“Conference was a great networking event and chance to get up-to-date on science and technologies out there and form new connections in key leaders in the filed”